SCHEMBL30765759

SCHEMBL30765759

CON(C)C(=O)CCCc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 5/20 0.57
FFAR1 O14842 4/20 0.55
PLAAT3 P53816 2/20 0.52
PLAAT5 Q96KN8 2/20 0.52
PLAAT2 Q9NWW9 2/20 0.52
PLAAT4 Q9UL19 2/20 0.52
SRD5A2 P31213 1/20 0.49
PPARG P37231 1/20 0.48
FFAR4 Q5NUL3 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPY5R Q15761 1/20 0.47
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829335 0.88 ALOX5 (0.61) ALOX5SMN1; SMN2ALDH1A1
SCHEMBL13792415 0.85 ALOX5 (0.77) ALOX5PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL1667586 0.84 ALOX5 (0.69) ALOX5SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6465764 0.81 ALOX5 (0.52) ALOX5SMN1; SMN2
SCHEMBL5321740 0.80 ALOX5 (0.55) ALOX5PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL27615885 0.79 FFAR1 (0.80) FFAR1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL1727025 0.79 KMT2A (0.62) ALOX5FFAR1ALDH1A1
SCHEMBL3868251 0.78 HSD17B10 (0.59) ALOX5
SCHEMBL8358797 0.78 CYP2D6 (0.58) FFAR1PPARGALDH1A1
SCHEMBL27472366 0.77 ALOX5 (0.61) ALOX5FFAR1PLAAT3PLAAT5PLAAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed